Showing 101-110 of 241 results for "".
Triple Threat
https://practicaldermatology.com/topics/general-topics/triple-threat/20629/In defense of the Aron Regimen for resistant atopic dermatitis.In The Pipeline: Phase 1, 2, and 3
https://practicaldermatology.com/programs/practical-dermatology-focus-psoriasis/pipeline-phase-1-2-and-3/29087/This summary provides the latest news on of some of the recent Phase 1, Phase 2, and Phase 3 clinical studies for psoriasis treatments.Close Up With Lawrence Eichenfield, MD
https://practicaldermatology.com/topics/atopic-dermatitis/close-up-with-lawrence-eichenfield-md/24018/Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-26/23564/Late-Stage Drugs for Atopic Dermatitis: An Update
https://practicaldermatology.com/topics/atopic-dermatitis/late-stage-drugs-for-atopic-dermatitis-an-update/23373/Here’s a look at investigational agents for this common disease.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-13/23272/Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-6/23116/Myth Busters: Taking the Mystery Out of Online Directories
https://practicaldermatology.com/topics/practice-management/myth-busters-taking-the-mystery-out-of-online-directories/20552/If you aren't managing your directory listings, someone else is. Learn how to take control of your information or online presence.Pain Relief for Next April 15th
https://practicaldermatology.com/topics/practice-management/pain-relief-for-next-april-15th--ivahevoh/18869/OJM Group Principal Carole Foos, CPA discusses strategies to help ease your individual and corporate tax burden for 2015 and years to come.To obtain a free copy of "Wealth Protection Planning for Dermatologists" visit the OJM Bookstore and enter the promo code DERMTUBE.Biologics and Pediatric Psoriasis
https://practicaldermatology.com/topics/practice-management/biologics-and-pediatric-psoriasis/21196/Though data has been lacking in recent years, the use of biologics in pediatric and adolescent patients deserves more consideration.